Evaluation of plasma arginine vasopressin in hypertonic saline test in patients with diencephalohypophysial diseases

Evaluation of plasma arginine vasopressin in hypertonic saline test in patients with diencephalohypophysial diseases - Evaluation of plasma arginine vasopressin in hypertonic saline test in patients with diencephalohypophysial diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020112

Enrollment

Registered

2015-12-08

Start date

2016-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes insipidus

Interventions

Hypertonic saline test 5% salt solution, 6 mL/kg, intravenous drip infusion for 2 hours

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with diencephalohypophysial diseases

Exclusion criteria

Exclusion criteria: Patients suspected of having diabetes insipidus (Serum Na concentration is not less than 147 mEq/L and daily urine volume is not less that 2000 mL)

Design outcomes

Primary

Measure	Time frame
Plasma AVP in hypertonic saline test	—

Countries

Japan

Contacts

Public ContactHiroshi Takagi

Nagoya University Graduate School of Medicine Department of Endocrinology and Diabetes

htakagi@med.nagoya-u.ac.jp052-744-2194

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026